Advanced Biomedical Research

Saffron for the management of premenstrual dysphoric disorder: A randomized controlled trial

Document Type : Original Article

Authors

1 Department of Psychiatry, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Selective serotonin reuptake inhibitors are among the most common agents have been used for the treatment of the premenstrual dysphoric disorder (PMDD); however, due to the diversity in the outcomes and adverse effects, efforts are in progress to find an agent with maximal efficacy and minimal adverse effects. Saffron is an herbal agent consisted of ingredients shown to act as an antidepressant, pain tranquilizer, and antioxidant. In the current study, it is aimed to assess the efficacy of saffron on PMDD treatment. Materials and Methods: In the current randomized controlled trial, 120 females with the diagnosis of PMDD were randomly allocated to three groups of treatment with fluoxetine (20 mg, twice daily), saffron (15 mg, twice daily) or placebo for 2 weeks in the luteal phase of two menstruation cycles. Daily record of severity of problems (DRSP) and Hamilton questionnaires had been filled before the interventions and then following the treatment cessation. The questionnaires' scores and drug-related adverse effects were compared among the studied groups. Results: Post-intervention assessment of three groups revealed significant improvement in all of the treatment approaches in terms of DRSP and Hamilton assessments (P < 0.001). Although DRSP assessments showed remarkable superiority of saffron to placebo (P = 0.027), Hamilton evaluations showed insignificant differences among the three interventions (P > 0.05). Fluoxetine posed a significantly higher rate of adverse effects as compared to the other agents (P = 0.01). Conclusion: Based on the findings of this study, saffron was an efficacious herbal agent for the treatment of PMDD with minimal adverse effects.

Keywords

1.
Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32.  Back to cited text no. 1
    
2.
de Carvalho AB, Cardoso TA, Mondin TC, da Silva RA, Souza LD, Magalhães PV, et al. Prevalence and factors associated with premenstrual dysphoric disorder: A community sample of young adult women. Psychiatry Res 2018;268:42-5.  Back to cited text no. 2
    
3.
O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: The ISPMD Montreal consensus. Arch Womens Ment Health 2011;14:13-21.  Back to cited text no. 3
    
4.
Dennerstein L, Lehert P, Bäckström TC, Heinemann K. The effect of premenstrual symptoms on activities of daily life. Fertil Steril 2010;94:1059-64.  Back to cited text no. 4
    
5.
Al-Hamzawi SA, Mohammed BK. Prevalence, socio-demographic variables, symptoms profile, and comorbidity of premenstrual dysphoric disorder. Int J Res Pharm Sci 2019;10:694-8.  Back to cited text no. 5
    
6.
Delara M, Borzuei H, Montazeri A. Premenstrual disorders: Prevalence and associated factors in a sample of Iranian adolescents. Iran Red Crescent Med J 2013;15:695-700.  Back to cited text no. 6
    
7.
Kraemer GR, Kraemer RR. Premenstrual syndrome: Diagnosis and treatment experiences. J Womens Health 1998;7:893-907.  Back to cited text no. 7
    
8.
Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol 2018;218:68-74.  Back to cited text no. 8
    
9.
Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003;28 Suppl 3:39-- 53.  Back to cited text no. 9
    
10.
Firoozi R, Kafi M, Salehi I, Shirmohammadi M. The relationship between severity of premenstrual syndrome and psychiatric symptoms. Iran J Psychiatry 2012;7:36-40.  Back to cited text no. 10
    
11.
Mishell DR Jr. Premenstrual disorders: Epidemiology and disease burden. Am J Manag Care 2005;11:S473-9.  Back to cited text no. 11
    
12.
Taavoni S, Barkhordari F, Goushegir A, Haghani H. Effect of Royal Jelly on premenstrual syndrome among Iranian medical sciences students: A randomized, triple-blind, placebo-controlled study. Complement Ther Med 2014;22:601-6.  Back to cited text no. 12
    
13.
Hantsoo L, Epperson CN. Premenstrual dysphoric disorder: Epidemiology and treatment. Curr Psychiatry Rep 2015;17:87.  Back to cited text no. 13
    
14.
Sepede G, Sarchione F, Matarazzo I, Di Giannantonio M, Salerno RM. Premenstrual dysphoric disorder without comorbid psychiatric conditions: A systematic review of therapeutic options. Clin Neuropharmacol 2016;39:241-61.  Back to cited text no. 14
    
15.
Pearlstein T. Treatment of premenstrual dysphoric disorder: Therapeutic challenges. Expert Rev Clin Pharmacol 2016;9:493-6.  Back to cited text no. 15
    
16.
Wyatt KM, Dimmock PW, Frischer M, Jones PW, O'Brien SP. Prescribing patterns in premenstrual syndrome. BMC Womens Health 2002;2:4.  Back to cited text no. 16
    
17.
Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, et al. Crocus sativus L. in the treatment of mild to moderate depression: A double-blind, randomized and placebo-controlled trial. Phytother Res 2005;19:148-51.  Back to cited text no. 17
    
18.
Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: A pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med 2004;4:12.  Back to cited text no. 18
    
19.
Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: A double-blind, randomized pilot trial. J Ethnopharmacol 2005;97:281-4.  Back to cited text no. 19
    
20.
Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, et al. Crocus sativus L.(saffron) in the treatment of premenstrual syndrome: A double-blind, randomised and placebo-controlled trial. BJOG 2008;115:515-9.  Back to cited text no. 20
    
21.
Hamilton M. A rating scale for depression J Neurol Neurosurg Psychiatry 1960;23:56-62.  Back to cited text no. 21
    
22.
Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Amazon.com; The United States of Americ. American Psychiatric Pub; 2013.  Back to cited text no. 22
    
23.
Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): Reliability and validity. Arch Womens Ment Health 2006;9:41-9.  Back to cited text no. 23
    
24.
Kialashaki A, Shokouhi F, Tofighi M, Zafari M, Zarenegad N. Effect of lavandula essence on premenstrual syndrome. J Mazandaran Univ Med Sci 2012;22:48-56.  Back to cited text no. 24
    
25.
Ozcan H, Oral E, Gulec M, Turkez H, Gulec TC, Ustundag MF, et al. Total oxidant–antioxidant and paraoxonase-1 levels in premenstrual dysphoric disorder: A follow-up study. Psychiatry Clin Psychopharmacol 2017;27:116-24.  Back to cited text no. 25
    
26.
Maharaj S, Trevino K. A comprehensive review of treatment options for premenstrual syndrome and premenstrual dysphoric disorder. J Psychiatr Pract 2015;21:334-50.  Back to cited text no. 26
    
27.
Beiranvand SP, Beiranvand NS, Moghadam ZB, Birjandi M, Azhari S, Rezaei E, et al. The effect of Crocus sativus (saffron) on the severity of premenstrual syndrome. Eur J Integr Med 2016;8:55-61.  Back to cited text no. 27
    
28.
Shoupe D. Diagnosis and Treatment of Premenstrual Syndrome: Differentiating PMS from Premenstrual Dysphoric Disorder PMDD and Premenstrual Exacerbation Disorder PMED. Handbook of Gynecology. University of Southern California, Los Angeles, CA, USA 2017. p. 181-5.  Back to cited text no. 28
    
29.
Mattina GF, Steiner M. Premenstrual Dysphoric Disorder. Women's Mental Health. Springer; 2020. p. 73-93.  Back to cited text no. 29
    
30.
Kleinstäuber M, Witthöft M, Hiller W. Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: A meta-analysis. J Clin Psychol Med Settings 2012;19:308-19.  Back to cited text no. 30
    
31.
Azhari S, Ahmadi S, Rakhshandeh H, Jafarzadeh H, Mazlom SR. Evaluation of the effect of oral saffron capsules on pain intensity during the active phase of labor. Iran J Obstet Gynecol Infertil 2014;17:1-10.  Back to cited text no. 31
    
32.
Marder M, Estiú G, Blanch LB, Viola H, Wasowski C, Medina JH, et al. Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepine binding site of the GABAA receptor complex. Bioorganic Med Chem 2001;9:323-35.  Back to cited text no. 32
    
33.
Ai J, Dekermendjian K, Wang X, Nielsen M, Witt MR. 6-Methylflavone, a benzodiazepine receptor ligand with antagonistic properties on rat brain and human recombinant GABAA receptors in vitro. Drug Dev Res 1997;41:99-106.  Back to cited text no. 33
    
34.
Boskabady MA, Aslani M. Relaxant effect of Crocus sativus (saffron) on guinea-pig tracheal chains and its possible mechanisms. J Pharm Pharmacol 2006;58:1385-90.  Back to cited text no. 34
    
35.
Hosseinzadeh H, Talebzadeh F. Anticonvulsant evaluation of safranal and crocin from Crocus sativus in mice. Fitoterapia 2005;76:722-4.  Back to cited text no. 35
    
Advanced Biomedical Research
Volume 2020, october
October 2020
Pages 1-7